Keros Therapeutics (KROS)

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
$0.67 (-1.00%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0

About

Business overview of Keros Therapeutics (KROS)
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.

Key Insights

Critical company metrics and information
  • Share Price

    $67.31
  • Market Cap

    $2.73 Billion
  • Total Outstanding Shares

    40.51 Million Shares
  • Total Employees

    160
  • Dividend

    No dividend
  • IPO Date

    April 8, 2020
  • SIC Description

    Pharmaceutical Preparations
  • Homepage

    https://www.kerostx.com

Historical Stock Splits

Execution DateSplit Amount
No Historical Stock Splits

Cash Flow Statement

July 1, 2024 to September 30, 2024
MetricValue
Net Cash Flow From Investing Activities, Continuing$-386,000.00
Net Cash Flow From Operating Activities$-30.50 Million
Net Cash Flow, Continuing$125.06 Million
Net Cash Flow$125.06 Million
Net Cash Flow From Financing Activities, Continuing$155.94 Million
Net Cash Flow From Investing Activities$-386,000.00
Net Cash Flow From Operating Activities, Continuing$-30.50 Million
Net Cash Flow From Financing Activities$155.94 Million

Income Statement

July 1, 2024 to September 30, 2024
MetricValue
Income/Loss From Continuing Operations Before Tax$388,000.00
Diluted Average Shares$37.59 Million
Net Income/Loss Attributable To Parent$-52.96 Million
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0.00
Net Income/Loss Available To Common Stockholders, Basic$-52.96 Million
Diluted Earnings Per Share$-1.41
Operating Expenses$59.05 Million
Preferred Stock Dividends And Other Adjustments$0.00
Income/Loss From Continuing Operations After Tax$-52.96 Million
Other Operating Expenses$9.82 Million
Net Income/Loss$-52.96 Million
Basic Earnings Per Share$-1.41
Benefits Costs and Expenses$0.00
Revenues$388,000.00
Net Income/Loss Attributable To Noncontrolling Interest$0.00
Costs And Expenses$59.05 Million
Basic Average Shares$37.59 Million
Nonoperating Income/Loss$5.70 Million
Research and Development$49.23 Million
Operating Income/Loss$-58.66 Million

Balance Sheet

July 1, 2024 to September 30, 2024
MetricValue
Other Current Liabilities$16.00 Million
Equity$532.84 Million
Fixed Assets$4.37 Million
Current Assets$552.05 Million
Wages$8.03 Million
Equity Attributable To Noncontrolling Interest$0.00
Equity Attributable To Parent$532.84 Million
Assets$579.27 Million
Accounts Payable$4.98 Million
Liabilities$46.44 Million
Liabilities And Equity$579.27 Million
Noncurrent Assets$27.23 Million
Current Liabilities$29.01 Million
Noncurrent Liabilities$17.43 Million
Other Non-current Assets$22.86 Million

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.